Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03165110 · ClinicalTrials.gov registry record · NA
Evaluation of an Ascensia Diabetes Care Blood Glucose Meter and App System
A NA study, sponsored by Ascensia Diabetes Care.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
NCT03165110: Completed NA study, sponsored by Ascensia Diabetes Care.
NCT03165110 is a NA study that has completed, run by Ascensia Diabetes Care. The registered enrollment target is 47 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03165110, a NA study, has completed, sponsored by Ascensia Diabetes Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the utility of the Contour Diabetes App 2.0 when used with the Contour Next One meter (the Onyx system).
Primary Outcome
Staff obtained responses from persons with diabetes using short questionnaires to provide feedback on the success of syncing the blood glucose value on the meter with the App for the Onyx Glucose Meter and App System. Subjects could respond '1Strongly Agree' or '2Agree' or '3Neither Agree nor Disagree' or '4Disagree' or '5Strongly Disagree' or '6No Opinion'.
Interventions
- DEVICE Onyx BG Meter / App System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-03-17 |
| Est. Completion | 2017-05-12 |
| Phase | NA |
What the finished NCT03165110 record still lists
NCT03165110 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Onyx BG Meter / App System is the first listed.
NCT03165110 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03165110 about?
NCT03165110 is a clinical study titled "Evaluation of an Ascensia Diabetes Care Blood Glucose Meter and App System". The purpose of this study is to assess the utility of the Contour Diabetes App 2.0 when used with the Contour Next One meter (the Onyx system).
What is the current status of trial NCT03165110?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2017-03-17. Estimated completion is 2017-05-12.
What interventions are being tested in trial NCT03165110?
The interventions under investigation include: Onyx BG Meter / App System (DEVICE).
Who is sponsoring clinical trial NCT03165110?
This trial is sponsored by Ascensia Diabetes Care, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03165110's enrollment target sits among peer trials
47 1400th of 2000 higher than 599 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI